Newsroom 2013

2013 Releases

05/12/2013
CSL signs agreement with Janssen to progress novel cancer therapy
CSL Limited has today announced an agreement with Janssen Biotech, Inc. that may one day lead to new treatments for haematological cancers and autoimmune diseases. More.

21/11/2013
CSL releases positive data for potential new heart attack therapy and announces next phase of clinical development
Results of a phase 2a trial of CSL112 in patients with stable cardiovascular disease have shown a dramatic and rapid increase in key indicators of reverse cholesterol transport, a process by which cholesterol is removed from arteries and transported to the liver for clearance. Rapid removal of cholesterol following a heart attack may be a new mechanism for stabilising vulnerable plaque lesions and lowering the high risk of subsequent attacks. More.

16/10/2013
CSL announces A$950m share buyback
CSL Limited (ASX:CSL) today announced a further on-market share buyback of up to A$950 million. Speaking at CSL’s Annual General Meeting in Melbourne today, CSL Chairman Professor John Shine said the Board was pleased to continue a buyback program that had clearly delivered benefits for shareholders. More.

07/10/2013
Agreement to settle U.S. antitrust class action litigation
Profit outlook re-affirmed, subject to settlement

CSL Limited (ASX:CSL) today announced that it has signed an agreement to settle the U.S. antitrust class action litigation, filed by certain U.S. and Puerto Rican hospital groups, which has been ongoing since 2009. The settlement agreement resolves and dismisses all claims and potential claims of class members against CSL in the lawsuit, as well as those against the Plasma Protein Therapeutics Association, an industry trade association. More.

14/08/2013
Full Year Results announcement for 2012/13
CSL Limited (ASX:CSL) today announced a net profit after tax (NPAT) of US$1,216 million for the twelve months ended 30 June 2013, up US$192 million or 19% on a reported basis when compared to the prior comparable period (PCP). The result included an unfavourable foreign exchange impact of US$18 million. On a constant currency1 basis, net profit after tax grew 21%, slightly ahead of guidance. Earnings per share grew 24%, benefiting from current and past capital management initiatives. More.

14/08/2013
CSL announces Changes to the Board
CSL Limited (ASX:CSL) today announced that Ms Marie McDonald has been appointed a Director effective from 14 August 2013. The Company also announced that Mr Ian Renard AM, has indicated his intention to retire from the CSL Board of Directors at the conclusion of the Company’s Annual General Meeting on 16 October 2013. More.

08/08/2013
Notice of Investor/Analyst Briefing - Result FY2013
CSL Limited (ASX:CSL) CSL Limited’s 2013 full year results will be announced on Wednesday, 14 August 2013.  More.

04/07/2013
CSL progresses new bleeding disorder therapies
CSL Limited has this week presented promising results from a number of clinical studies involving a new group of therapies for the treatment of haemophilia. More.

28/06/2013
Terms of Departure of Managing Director and CEO
CSL Limited (ASX:CSL) has previously announced that Dr Brian McNamee will be succeeded by Mr Paul Perreault as Managing Director and Chief Executive Officer of CSL from 1 July 2013. More.

19/06/2013
CSL Limited - Changes to Segment Reporting
In February 2013, the Company announced the completion of the reorganisation of its Australian Operations which took effect from 1 January 2013 and advised that financial reporting reflecting this new organisational structure would be shown in the segment reporting commencing with the FY2013 results. More.

29/04/2013
bioCSL Awarded Major Vaccine Distribution Contracts
bioCSL has been selected by New South Wales Health (NSW Health) and the Western Australian Department of Health (WA DoH) to provide storage and distribution services for government funded vaccine programs. The contracts, awarded after separate tender processes, have a combined value of $6.8 million. More.

05/04/2013
CSL Half Year Report 2012-13
bioCSL has been selected by New South Wales Health (NSW Health) and the Western Australian Department of Health (WA DoH) to provide storage and distribution services for government funded vaccine programs. The contracts, awarded after separate tender processes, have a combined value of $6.8 million. More.

28/03/2013
New US$500 million Private Placement
CSL Limited (ASX:CSL) is pleased to announce that on 27 March 2013 it closed a new US$500m Private Placement in the US. More.

08/03/2013
Terms of Appointment of Managing Director and CEO
CSL Limited (ASX:CSL) has previously announced that Mr Paul Perreault will succeed Dr Brian McNamee as Managing Director and Chief Executive Officer of CSL from 1 July 2013. More.

13/02/2013
Half Year Results announcement for 2012/13
CSL Limited (ASX:CSL) today announced a net profit after tax of US$627 million for the six months ended 31 December 2012, up US$123 million or 24% on a reported basis when compared to the prior comparable period (PCP). Earnings per share grew 30%, benefiting from current and past capital management initiatives. More.

13/02/2013
Appointment of Paul Perreault as Executive Director
CSL Limited (ASX:CSL) is pleased to announce the appointment of Mr Paul Perreault to the CSL Limited Board as an Executive Director effective 13 February 2013. More.

13/02/2013
Change to 2013 Dividend Payment Dates
CSL Limited (ASX:CSL) is pleased to announce that, in line with its previous announcement on 17 December 2012 to bring forward the announcement of its Half Year and Full Year Results Announcements by one week, it will also bring forward the payment date of its interim and full year dividends by one week. More.

© 2016 CSL Limited